{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-010105","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.672898+00:00","generated_at":"2026-05-15T08:38:21.614116+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Pulse Biosciences awards CTO Darrin Uecker 100,000 RSUs for AFib product development","bullets":["Restricted stock units cover 100,000 shares of common stock, par value $0.001.","Grant vests in full on third anniversary of March 23, 2026 grant date.","Award made under Amended and Restated 2017 Equity Incentive Plan.","Compensation Committee granted for continued leadership in atrial fibrillation treatment product development."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-010105","json":"https://secwatch.observer/filing/0001437749-26-010105.json","markdown":"https://secwatch.observer/filing/0001437749-26-010105.md","text":"https://secwatch.observer/filing/0001437749-26-010105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926010105/0001437749-26-010105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926010105/plse20260327_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:38:21.614116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}